Canadian Medication Cost Savings Associated with Combinatorial Pharmacogenomic Guidance for Psychiatric Medications

Figures & data

Table 1 Demographics of the Patient Sample, Based on Congruence with the Combinatorial Pharmacogenomic Test at Follow-Up

	Full Cohort	Patients on Congruent Medications	Patients on Incongruent Medications	p-Value^a
Total, N (% of total)	1662 (100.0%)	1301 (78.3%)	361 (21.7%)	–
Male, N (%)	511 (30.7%)	397 (30.5%)	114 (31.6%)	0.68
Age, Mean (SD)	53.3 (16.9)	52.6 (17.0)	55.6 (16.6)	0.003
Age <65 years, N (%)	1277 (76.8%)	1022 (78.6%)	255 (70.6%)	0.002
Total medication fills, Mean (SD)	43.8 (30.0)	42.5 (28.9)	48.2 (33.5)	0.01
Total CNS medication fills, Mean (SD)	23.5 (17.8)	22.6 (17.1)	26.7 (19.7)	0.0001
Diagnosis
Major Depressive Disorder, N (%)	459 (27.6%)	362 (27.8%)	97 (26.9%)	0.72
Generalized Anxiety Disorder, N (%)	318 (19.1%)	261 (20.1%)	57 (15.8%)	0.06
Bipolar Disorder, N (%)	90 (5.4%)	69 (5.3%)	21 (5.8%)	0.71
Other, N (%)^b	1104 (66.4%)	874 (67.2%)	230 (63.7%)	0.22

Notes: ^ap-value patients taking medications that were congruent compared to incongruent with their test report. ^bRefers to patients who had non-mental health diagnoses or no diagnostic code.

Figure 1 Annual medication costs with patients stratified by congruence with combinatorial pharmacogenomic test report recommendations. (A) Total medication costs. (B) CNS medication costs. (C) Non-CNS medication costs.

Figure 2 Annual medication costs according to patient age group (<65 and ≥65 years) and stratified by congruence with combinatorial pharmacogenomic test report recommendations. (A) Total medication costs. (B) CNS medication costs. (C) Non-CNS medication costs.

Data Availability

This study included a secondary analysis of previously published data. Please refer to Winner et al 2015 for information on data access.